BI 1839100 is an investigational medication being studied for its potential to reduce cough frequency in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis. This medication is taken orally and is being tested to see how effective and safe it is over a 12-week treatment period. The study aims to find the right dose that can significantly decrease the number of coughs a patient experiences in a day.

Idiopathic Pulmonary Fibrosis (IPF) – A chronic lung disease characterized by the thickening and scarring of lung tissue, leading to a progressive decline in lung function. The cause of IPF is unknown, and it primarily affects middle-aged and older adults. As the disease progresses, the scarring makes it increasingly difficult for the lungs to transfer oxygen into the bloodstream. Patients often experience a persistent dry cough and shortness of breath, which worsen over time. The disease can lead to a significant reduction in the ability to perform daily activities due to breathing difficulties.

Progressive Pulmonary Fibrosis (PPF) – A condition where lung tissue becomes damaged and scarred over time, leading to a gradual worsening of lung function. This disease can arise from various underlying causes, including other lung conditions or environmental exposures. As fibrosis progresses, patients may experience increasing breathlessness and a chronic cough. The scarring of lung tissue reduces the lungs’ ability to expand and contract, making breathing more difficult. Over time, the disease can severely impact the quality of life due to the progressive nature of the symptoms.